Articles
Updated 2/28/20 Samumed SM04554 Phase 3 Trial Is Now Fully Enrolled In a company newsletter published on February 28, 2020, Samumed announced that their phase 3 trial of SM04454 in AGA has finally reached its quota of trial participants. That quota was a whopping 625 male subjects between the ages of 18 – 45 years…
(Updated Below) As the company promised to do earlier this month, Follicum has released data from its phase 2a study which concluded in August earlier this year. This was the first trial Follicum conducted using FOL-005, a modified peptide, on human scalps. In this recent scalp study, five doses (including placebo) were evaluated where patients…
One of the most fascinating companies in the hair restoration industry, HairClone, has been featured in the latest edition of the UK’s Consulting Room online magazine. The article features commentary from HairClone CEO Paul Kemp PhD and Medical Director Dr. Bessam Farjo. The article by Lorna Jackson is very detail oriented and provides a comprehensive…
According to its latest news update, Follicum will present top-line data from its recent phase 2a trial by the end of the month. The phase 2a trial for Follicum’s hair growth candidate FOL-005 was completed at sites in Hamburg and Berlin, Germany at the end of August this year. The study comprised 60 patients (assumed…
Updated After a long wait we finally have the answer. The “Brotzu Lotion” aka Trinov is going to be released by Fidia Pharma this year. The press release shown above was posted on Fidia’s official website today only in the Italian version. The key points from the announcement are as follows: Production on Trinov has…
British hair-cell cloning company HairClone has released its latest newsletter on September 10th. This is the second newsletter of the year from HairClone, the company previously published a newsletter in February. HairClone typically divides its news updates into two categories, business and science. It’s interesting to follow HairClone’s progress in these regards and see how…
The Guardian has reported the intriguing drug WAY-316606, which was originally developed for osteoporosis, may soon be entering human hair growth clinical trials with the help of an Italian pharmaceutical company. I was pleasantly surprised to find some worthwhile information in the latest “mainstream media baldness cure” article published by The Guardian today. I should…
Another important milestone has been achieved by the Swedish biotech company Follicum. Today, Follicum announced that all patients participating in their phase 2a clinical trial have completed treatment. The phase 2a trial took place at centers in Berlin and Hamburg, Germany and was carried out over the past 3 months. 60 subjects participated and received…
It looks like we may have another approved treatment on the market within the next 2 years. Today, Samumed released a newsletter addressing its program for androgenic alopecia, and stated that the company “has conducted an Investigator Meeting to initiate our upcoming 625-patient Phase 3 clinical trial.” While the results from the phase 2 trial…
About 3.5 years ago the Sanford Burnham Prebys medical research institute released an article that received major attention in the hair seeker community and in the mainstream media. SBP researcher Alexey Terskikh PhD had just published a peer reviewed article detailing his work turning human embryonic stem cells (hESCs) into hair-producing dermal papillae cells. It…